Theresa Liu Dumlao

Learn More
We measured histone deacetylase (HDAC) activity in 17 patients with primary myelofibrosis (PMF); 19 with other myeloproliferative neoplasm (MPN) and 16 normal volunteers. Significantly elevated HDAC levels were shown in patients with PMF compared with other MPN patients and normal volunteers (p<0.05). Sixteen patients with PMF were also studied for(More)
e11519^ Background: The TAC regimen (docetaxel, doxorubicin, and cyclophosphamide) is among the most active drug combinations in the adjuvant and neoadjuvant settings. A recent study demonstrated that weekly nab-paclitaxel (N) is superior to every-three week docetaxel in both efficacy and toxicity in patients with metastatic breast cancer. Here we report(More)
Dasatinib is a second generation tyrosine kinase inhibitor, with activity in imatinib resistant Ph-positive ALL.We have treated 34 patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia(ALL) (n519) or lymphoid blast phase of chronic myelogenous leukemia (CML-LB) (n515) with the combination of dasatinib and the hyper CVAD(More)
3095^ Background: The efficacy of nanoparticle albumin bound paclitaxel (N) seems to correlate with the expression of tumor-associated SPARC. A common mechanism for SPARC downregulation is hypermethylation. This study investigates the use of the hypomethylating agent azacitadine (A), followed by N in the treatment of refractory advanced solid tumors. (More)
BACKGROUND Secreted protein acidic and rich in cysteine (SPARC), an albumin-binding protein, is downregulated by hypermethylation in many cancers. Hypomethylating agents such as azacitidine can upregulate SPARC in tumors, which may enhance the accumulation of albumin-bound drugs at tumor site. The objectives of this phase I trial was to determine the safety(More)
BACKGROUND The aims of this study were to assess the safety and tolerability of nanoparticle albumin bound paclitaxel (nab-paclitaxel), doxorubicin, and cyclophosphamide as combination therapy for breast cancer patients in the neoadjuvant setting and to assess the overall clinical response and pathologic complete response (pCR). PATIENTS AND METHODS(More)
  • 1